Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Cytori Therapeutics (CYTX) Competitors

Cytori Therapeutics logo

CYTX vs. SABS, CRIS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, BIIB, and UTHR

Should you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry.

Cytori Therapeutics vs. Its Competitors

Cytori Therapeutics (NASDAQ:CYTX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

SAB Biotherapeutics has a consensus price target of $13.00, suggesting a potential upside of 409.80%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Cytori Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytori Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
SAB Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

SAB Biotherapeutics has a net margin of 0.00% compared to Cytori Therapeutics' net margin of -242.60%. SAB Biotherapeutics' return on equity of -105.14% beat Cytori Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytori Therapeutics-242.60% -272.70% -56.23%
SAB Biotherapeutics N/A -105.14%-69.24%

Cytori Therapeutics has higher revenue and earnings than SAB Biotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytori Therapeutics$3.67M3.20-$12.63MN/AN/A
SAB Biotherapeutics$1.32M17.95-$34.10M-$3.70-0.69

Cytori Therapeutics has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500.

2.6% of Cytori Therapeutics shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 0.7% of Cytori Therapeutics shares are held by insiders. Comparatively, 27.8% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, SAB Biotherapeutics had 9 more articles in the media than Cytori Therapeutics. MarketBeat recorded 9 mentions for SAB Biotherapeutics and 0 mentions for Cytori Therapeutics. SAB Biotherapeutics' average media sentiment score of 0.51 beat Cytori Therapeutics' score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cytori Therapeutics Neutral
SAB Biotherapeutics Positive

Summary

SAB Biotherapeutics beats Cytori Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Cytori Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYTX vs. The Competition

MetricCytori TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$11.74M$66.53M$5.74B$9.54B
Dividend YieldN/AN/A4.71%4.02%
P/E RatioN/A6.5528.4120.06
Price / Sales3.20148.79443.6492.77
Price / CashN/A18.4136.1858.54
Price / Book1.518.188.655.87
Net Income-$12.63M-$25.92M$3.25B$258.89M

Cytori Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYTX
Cytori Therapeutics
N/A$0.53
-11.2%
N/A-71.7%$11.74M$3.67M0.0037High Trading Volume
SABS
SAB Biotherapeutics
3.6799 of 5 stars
$2.61
-3.3%
$13.00
+398.1%
-8.9%$25.08M$1.32M-0.71140News Coverage
Analyst Forecast
Analyst Revision
Gap Down
High Trading Volume
CRIS
Curis
2.5695 of 5 stars
$1.82
+4.6%
$17.00
+834.1%
-69.9%$18.20M$10.91M-0.2960Positive News
Upcoming Earnings
BOLT
Bolt Biotherapeutics
2.7067 of 5 stars
$5.95
+3.7%
$50.00
+740.3%
-57.9%$10.99M$7.69M-0.1890Positive News
High Trading Volume
AMGN
Amgen
4.3319 of 5 stars
$305.69
+3.3%
$308.77
+1.0%
-8.4%$159.09B$33.42B27.8928,000Positive News
Analyst Forecast
GILD
Gilead Sciences
4.9093 of 5 stars
$110.17
+1.7%
$111.38
+1.1%
+50.9%$134.69B$28.75B23.1917,600Trending News
Analyst Upgrade
VRTX
Vertex Pharmaceuticals
4.3198 of 5 stars
$470.13
+2.5%
$511.71
+8.8%
-5.2%$117.74B$11.02B-119.936,100Positive News
Analyst Revision
REGN
Regeneron Pharmaceuticals
4.8269 of 5 stars
$560.93
+2.8%
$814.57
+45.2%
-47.8%$58.90B$14.20B14.2815,106Trending News
Upcoming Earnings
Analyst Forecast
ALNY
Alnylam Pharmaceuticals
4.0795 of 5 stars
$325.28
+1.5%
$347.75
+6.9%
+40.0%$41.79B$2.25B-155.642,230News Coverage
Positive News
Upcoming Earnings
BIIB
Biogen
4.8088 of 5 stars
$127.85
+4.2%
$186.37
+45.8%
-37.7%$17.98B$9.68B12.627,605Upcoming Earnings
Analyst Revision
UTHR
United Therapeutics
4.9909 of 5 stars
$297.89
+1.6%
$383.08
+28.6%
-10.0%$13.22B$2.88B11.891,305Trending News
Upcoming Earnings
Insider Trade
Analyst Revision

Related Companies and Tools


This page (NASDAQ:CYTX) was last updated on 7/27/2025 by MarketBeat.com Staff
From Our Partners